Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Why hormones protect against large bowel cancer: old ideas, new evidence.

Newcomb PA, Pocobelli G, Chia V.

Adv Exp Med Biol. 2008;617:259-69. doi: 10.1007/978-0-387-69080-3_24. Review. No abstract available.

PMID:
18497049
2.

Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer.

Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR.

Cancer Causes Control. 2007 Sep;18(7):723-33. Epub 2007 Jun 5.

PMID:
17549595
3.

Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: personal and lifestyle factors (United States).

Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD.

Cancer Causes Control. 2005 Oct;16(8):917-27.

PMID:
16132801
4.

Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.

Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C.

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1724-31.

5.

The rise and fall of menopausal hormone therapy.

Barrett-Connor E, Grady D, Stefanick ML.

Annu Rev Public Health. 2005;26:115-40. Review.

PMID:
15760283
7.

Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P.

Endocr Relat Cancer. 2004 Sep;11(3):537-51. Review.

8.

Defining hormone replacement therapy in longitudinal studies: impact on measures of effect.

Csizmadi I, Collet JP, Benedetti A, Boivin JF, Hanley JA.

Pharmacoepidemiol Drug Saf. 2004 Apr;13(4):215-25.

PMID:
15255088
9.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee.

JAMA. 2004 Apr 14;291(14):1701-12.

PMID:
15082697
10.

Estrogen plus progestin and colorectal cancer in postmenopausal women.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E; Women's Health Initiative Investigators.

N Engl J Med. 2004 Mar 4;350(10):991-1004.

11.

The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women.

Csizmadi I, Collet JP, Benedetti A, Boivin JF, Hanley JA.

Br J Cancer. 2004 Jan 12;90(1):76-81.

12.

Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation.

Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG.

Eur J Cancer. 2003 Jun;39(9):1251-8.

PMID:
12763213
13.

Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies.

Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C.

Int J Cancer. 2003 Jun 20;105(3):408-12.

14.

Menopausal hormone replacement therapy and risk of ovarian cancer.

Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C.

JAMA. 2002 Jul 17;288(3):334-41. Erratum in: JAMA 2002 Nov 27;288(20):2544.

PMID:
12117398
15.

Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997.

Pukkala E, Tulenheimo-Silfvast A, Leminen A.

Cancer Causes Control. 2001 Feb;12(2):111-5.

PMID:
11246839
16.

Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.

Heald A, Selby PL, White A, Gibson JM.

Am J Obstet Gynecol. 2000 Sep;183(3):593-600.

PMID:
10992179
17.

Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis.

Nanda K, Bastian LA, Hasselblad V, Simel DL.

Obstet Gynecol. 1999 May;93(5 Pt 2):880-8.

PMID:
10912438
18.

A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer.

Prihartono N, Palmer JR, Louik C, Shapiro S, Rosenberg L.

Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):443-7.

19.

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R.

JAMA. 2000 Jan 26;283(4):485-91. Erratum in: JAMA 2000 Nov 22-29;284(20):2597.

PMID:
10659874
20.

Estrogen replacement therapy and colorectal cancer risk in elderly women.

Paganini-Hill A.

Dis Colon Rectum. 1999 Oct;42(10):1300-5.

PMID:
10528768

Supplemental Content

Support Center